Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, announced the pricing of its public offering of 2,439,025 shares of its common stock at a public offering price of $41.00 per share.
February 17, 2021
· 5 min read